So, well, first off, I will say as my mentor was dying, he died of cancer, sadly
The dataset connects claims, labs and EHR, including physician notes to analyse: Who meets drug label or payer criteria based on actual BMI and comorbidities How titration and dosing progress in real-world care What metabolic outcomes patients achieve over time Which safety signals, such as liver or renal changes, emerge across populations Why patients discontinue or switch treatments, as documented in notes See real-world GLP-1 evidence in action Register for our webinar where we dive deeper into GLP-1 real-world evidence
We considered that GSTM2 was likely be more stable than GSTM1 from a genetic perspective, and therefore, up-regulating GSTM2 may be a better choice for inducing protective effects
Picrosirius red staining showed substantial fibrosis in both male and female SKO mice when compared to WT mice ( Figures 3C, D )
Combined with baseline micronutrient screening, this can inform a personalized treatment conversation with your provider